I fase 3 GIST - undersøgelsen forekommer behandlingsrelateret fatal gastrointestinal blødning hos 0, 5% af patienterne, der får placebo.
Treatment-related fatal gastrointestinal bleeding occurred in 0.5% of patients receiving placebo in the GIST Phase 3 study.